CY1109121T1 - Θεραπεια μυκητιασικων μολυνσεων - Google Patents

Θεραπεια μυκητιασικων μολυνσεων

Info

Publication number
CY1109121T1
CY1109121T1 CY20091100606T CY091100606T CY1109121T1 CY 1109121 T1 CY1109121 T1 CY 1109121T1 CY 20091100606 T CY20091100606 T CY 20091100606T CY 091100606 T CY091100606 T CY 091100606T CY 1109121 T1 CY1109121 T1 CY 1109121T1
Authority
CY
Cyprus
Prior art keywords
fungal infection
infection therapy
antibody
composition
therapy
Prior art date
Application number
CY20091100606T
Other languages
English (en)
Inventor
James Peter Burnie
Ruth Christine Matthews
Original Assignee
Neutec Pharma Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Neutec Pharma Limited filed Critical Neutec Pharma Limited
Publication of CY1109121T1 publication Critical patent/CY1109121T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/14—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from fungi, algea or lichens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Mycology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Genetics & Genomics (AREA)
  • Communicable Diseases (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Σύνθεση που περιλαμβάνει αντίσωμα ή θραύσμα δέσμευσης αντιγόνου αυτού, ειδικό για τουλάχιστον έναν επίτοπο της hsp90, από οργανισμό του γένους Aspergillus, και τουλάχιστον έναν αντιμυκητιασικό παράγοντα που επιλέγεται από την ομάδα που περιλαμβάνει: την ιτρακοναζόλη και τη βορικοναζόλη.
CY20091100606T 2004-04-23 2009-06-09 Θεραπεια μυκητιασικων μολυνσεων CY1109121T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0409077.5A GB0409077D0 (en) 2004-04-23 2004-04-23 Treatment of fungal infections
EP05734312A EP1737488B1 (en) 2004-04-23 2005-04-18 Treatment of fungal infections

Publications (1)

Publication Number Publication Date
CY1109121T1 true CY1109121T1 (el) 2014-07-02

Family

ID=32344282

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20091100606T CY1109121T1 (el) 2004-04-23 2009-06-09 Θεραπεια μυκητιασικων μολυνσεων

Country Status (30)

Country Link
US (1) US7785571B2 (el)
EP (3) EP2044954A1 (el)
JP (1) JP2007533716A (el)
KR (1) KR20080024944A (el)
CN (1) CN1946424A (el)
AT (1) ATE424846T1 (el)
AU (1) AU2005235339B2 (el)
BR (1) BRPI0510052A (el)
CA (1) CA2564137A1 (el)
CY (1) CY1109121T1 (el)
DE (1) DE602005013197D1 (el)
DK (1) DK1737488T3 (el)
EC (1) ECSP067022A (el)
ES (1) ES2322171T3 (el)
GB (1) GB0409077D0 (el)
HK (1) HK1100320A1 (el)
HR (1) HRP20090261T1 (el)
IL (1) IL178565A0 (el)
MA (1) MA28717B1 (el)
MX (1) MXPA06012256A (el)
NO (1) NO20065246L (el)
NZ (1) NZ550450A (el)
PL (1) PL1737488T3 (el)
PT (1) PT1737488E (el)
RU (1) RU2380116C2 (el)
SG (1) SG152269A1 (el)
SI (1) SI1737488T1 (el)
TN (1) TNSN06339A1 (el)
WO (1) WO2005102386A1 (el)
ZA (1) ZA200608767B (el)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100113355A1 (en) * 2007-04-27 2010-05-06 Naresh Chennamsetty Novel antibody molecules and nucleic acids binding to fungal stress protein hsp90
JP5925783B2 (ja) * 2011-08-12 2016-05-25 国立感染症研究所長 アスペルギルスフミガーツス感染症の検査、予防及び治療のための方法並びに組成物
CN113845591B (zh) * 2018-10-30 2023-10-31 迈威(上海)生物科技股份有限公司 Hsp90抗体及其在抗真菌感染中的应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8915019D0 (en) 1989-06-30 1989-08-23 Matthews Ruth C Medicaments
US5952300A (en) 1996-04-19 1999-09-14 Merck & Co., Inc. Antifungal compositions
GB0008305D0 (en) 2000-04-06 2000-05-24 Neutec Pharma Plc Treatment of fungal infections
AU2003282806A1 (en) 2002-09-23 2004-04-08 Schering Corporation Use of posaconazole for the treatment of fungal infections

Also Published As

Publication number Publication date
ECSP067022A (es) 2007-02-28
NZ550450A (en) 2009-02-28
ATE424846T1 (de) 2009-03-15
SG152269A1 (en) 2009-05-29
ES2322171T3 (es) 2009-06-17
JP2007533716A (ja) 2007-11-22
ZA200608767B (en) 2008-06-25
GB0409077D0 (en) 2004-05-26
HK1100320A1 (en) 2007-09-14
DE602005013197D1 (de) 2009-04-23
AU2005235339A1 (en) 2005-11-03
WO2005102386A1 (en) 2005-11-03
AU2005235339B2 (en) 2010-11-25
DK1737488T3 (da) 2009-07-06
MA28717B1 (fr) 2007-07-02
CA2564137A1 (en) 2005-11-03
EP1737488B1 (en) 2009-03-11
US7785571B2 (en) 2010-08-31
RU2006141354A (ru) 2008-05-27
CN1946424A (zh) 2007-04-11
RU2380116C2 (ru) 2010-01-27
KR20080024944A (ko) 2008-03-19
BRPI0510052A (pt) 2007-10-16
TNSN06339A1 (en) 2008-02-22
PL1737488T3 (pl) 2009-08-31
NO20065246L (no) 2006-11-15
IL178565A0 (en) 2007-02-11
MXPA06012256A (es) 2007-06-15
US20080095778A1 (en) 2008-04-24
EP1737488A1 (en) 2007-01-03
HRP20090261T1 (en) 2009-07-31
EP2039369A1 (en) 2009-03-25
EP2044954A1 (en) 2009-04-08
SI1737488T1 (sl) 2009-08-31
PT1737488E (pt) 2009-05-11

Similar Documents

Publication Publication Date Title
WO2004016750A3 (en) FcϜRIIB-SPECIFIC ANTIBODIES AND METHODS OF USE THEREOF
CY1112277T1 (el) ΑΝΘΡΩΠΟΠΟΙΗΜΕΝΟΙ ΑΝΤΑΓΩΝΙΣΤΕΣ ΑΝΤΙ-β7 ΚΑΙ ΧΡΗΣΕΙΣ ΑΥΤΩΝ
CY1110783T1 (el) Μονοκλωνικα αντισωματα κατα αυξητικου παραγοντα ηπατοκυτταρων
EP1797893A3 (en) Phosphorylcholine conjugates and corresponding antibodies
IL214325A (en) Antibody against cmet, a drug that includes and uses it
WO2007022520A3 (en) Antibody-mediated enhancement of immune response
WO2005010048A3 (en) Rg1 antibodies and uses thereof
DE60138867D1 (de) Medikament zum Schutz gegen thrombotische Krankheiten
GB0008305D0 (en) Treatment of fungal infections
WO2005067956A3 (en) Use of interleukin-21 for the treatment of autoimune diseases and allograft rejection
WO2002075274A3 (fr) Methode et trousse pour le suivi des maladies neurodegeneratives
ATE461219T1 (de) Therapeutische humanisierte antikörper gegen cd45-isoformen
WO2002057794A3 (en) Compositions and methods for detection of ehrlichia canis and ehrlichia chaffeensis antibodies
CY1109121T1 (el) Θεραπεια μυκητιασικων μολυνσεων
DK1411962T3 (da) Terapi for pancreacancer med monoklonalt stof
DE60141297D1 (de) Gegen das menschliche bst2 antigen gerichteter monoklonaler antikörper
AR055072A1 (es) Uso de anticuerpos anti- madcam para el tratamiento de enfermedad celiaca y esprue tropical
WO2005086967A3 (en) Therapeutic use of rm1 antigen